|
1
|
Yang C, Zhang Y, Zhang Y, Zhang Z, Peng J,
Li Z, Han L, You Q, Chen X, Rao X, et al: Downregulation of cancer
stem cell properties via mTOR signaling pathway inhibition by
rapamycin in nasopharyngeal carcinoma. Int J Oncol. 47:909–917.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lo KW, To KF and Huang DP: Focus on
nasopharyngeal carcinoma. Cancer Cell. 5:423–428. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shueng PW, Shen BJ, Wu LJ, Liao LJ, Hsiao
CH, Lin YC, Cheng PW, Lo WC, Jen YM and Hsieh CH: Concurrent
image-guided intensity modulated radiotherapy and chemotherapy
following neoadjuvant chemotherapy for locally advanced
nasopharyngeal carcinoma. Radiat Oncol. 6:952011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lee AW, Ng WT, Chan YH, Sze H, Chan C and
Lam TH: The battle against nasopharyngeal cancer. Radiother Oncol.
104:272–278. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stoker SD, van Diessen JN, de Boer JP,
Karakullukcu B, Leemans CR and Tan IB: Current treatment options
for local residual nasopharyngeal carcinoma. Curr Treat Options
Oncol. 14:475–491. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen YH, Wei MF, Wang CW, Lee HW, Pan SL,
Gao M, Kuo SH, Cheng AL and Teng CM: Dual phosphoinositide
3-kinase/mammalian target of rapamycin inhibitor is an effective
radiosensitizer for colorectal cancer. Cancer Lett. 357:582–590.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li JR, Cheng CL, Yang CR, Ou YC, Wu MJ and
Ko JL: Dual inhibitor of phosphoinositide 3-kinase/mammalian target
of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant
urothelial cancer cell growth through autophagic flux. Toxicol
Lett. 220:267–276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yuan TL and Cantley LC: PI3K pathway
alterations in cancer: Variations on a theme. Oncogene.
27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hong SW, Shin JS, Moon JH, Kim YS, Lee J,
Choi EK, Ha SH, Lee DH, Chung HN, Kim JE, et al: NVP-BEZ235, a dual
PI3K/mTOR inhibitor, induces cell death through alternate routes in
prostate cancer cells depending on the PTEN genotype. Apoptosis.
19:895–904. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Maira SM, Stauffer F, Brueggen J, Furet P,
Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker
K, et al: Identification and characterization of NVP-BEZ235, a new
orally available dual phosphatidylinositol 3-kinase/mammalian
target of rapamycin inhibitor with potent in vivo antitumor
activity. Mol Cancer Ther. 7:1851–1863. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Muranen T, Selfors LM, Worster DT,
Iwanicki MP, Song L, Morales FC, Gao S, Mills GB and Brugge JS:
Inhibition of PI3K/mTOR leads to adaptive resistance in
matrix-attached cancer cells. Cancer Cell. 21:227–239. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dubrovska A, Kim S, Salamone RJ, Walker
JR, Maira SM, García-Echeverría C, Schultz PG and Reddy VA: The
role of PTEN/Akt/PI3K signaling in the maintenance and viability of
prostate cancer stem-like cell populations. Proc Natl Acad Sci USA.
106:268–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qian XJ, Li YT, Yu Y, Yang F, Deng R, Ji
J, Jiao L, Li X, Wu RY, Chen WD, et al: Inhibition of DNA
methyltransferase as a novel therapeutic strategy to overcome
acquired resistance to dual PI3K/mTOR inhibitors. Oncotarget.
6:5134–5146. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ishikawa C, Senba M and Mori N: Effects of
NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target
of rapamycin inhibitor, on HTLV-1-infected T-cell lines. Oncol
Lett. 15:5311–5317. 2018.PubMed/NCBI
|
|
15
|
Wang D, Gao L, Liu X, Yuan C and Wang G:
Improved antitumor effect of ionizing radiation in combination with
rapamycin for treating nasopharyngeal carcinoma. Oncol Lett.
14:1105–1108. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma BB, Lui VW, Hui CW, Lau CP, Wong CH,
Hui EP, Ng MH, Cheng SH, Tsao SW, Tsang CM, et al: Preclinical
evaluation of the mTOR-PI3K inhibitor BEZ235 in nasopharyngeal
cancer models. Cancer Lett. 343:24–32. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Martini M, De Santis MC, Braccini L,
Gulluni F and Hirsch E: PI3K/AKT signaling pathway and cancer: An
updated review. Ann Med. 46:372–383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Serra V, Markman B, Scaltriti M, Eichhorn
PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S,
et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K
signaling and inhibits the growth of cancer cells with activating
PI3K mutations. Cancer Res. 68:8022–8030. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Guertin DA, Stevens DM, Thoreen CC, Burds
AA, Kalaany NY, Moffat J, Brown M, Fitzgerald KJ and Sabatini DM:
Ablation in mice of the mTORC components raptor, rictor, or mLST8
reveals that mTORC2 is required for signaling to Akt-FOXO and
PKCalpha, but not S6K1. Dev Cell. 11:859–871. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ocana A, Vera-Badillo F, Al-Mubarak M,
Templeton AJ, Corrales-Sanchez V, Diez-Gonzalez L, Cuenca-Lopez MD,
Seruga B, Pandiella A and Amir E: Activation of the PI3K/mTOR/AKT
pathway and survival in solid tumors: Systematic review and
meta-analysis. PLoS One. 9:e952192014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Benjamin D, Colombi M, Moroni C and Hall
MN: Rapamycin passes the torch: A new generation of mTOR
inhibitors. Nat Rev Drug Discov. 10:868–880. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ghayad SE, Bieche I, Vendrell JA, Keime C,
Lidereau R, Dumontet C and Cohen PA: mTOR inhibition reverses
acquired endocrine therapy resistance of breast cancer cells at the
cell proliferation and gene-expression levels. Cancer Sci.
99:1992–2003. 2008.PubMed/NCBI
|
|
24
|
Ma Y, Vassetzky Y and Dokudovskaya S:
mTORC1 pathway in DNA damage response. Biochim Biophys Acta.
1865:1293–1311. 2018. View Article : Google Scholar
|
|
25
|
Balaji S, Ahmed M, Lorence E, Yan F, Nomie
K and Wang M: NF-kappaB signaling and its relevance to the
treatment of mantle cell lymphoma. J Hematol Oncol. 11:832018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang C, Peng J, Jiang W, Zhang Y, Chen X,
Wu X, Zhu Y, Zhang H, Chen J, Wang J, et al: mTOR activation in
immature cells of primary nasopharyngeal carcinoma and anti-tumor
effect of rapamycin in vitro and in vivo. Cancer Lett. 341:186–194.
2013. View Article : Google Scholar : PubMed/NCBI
|
